Alternative and Complementary Therapies for Cancer
Moulay Alaoui-Jamali
Editor

Alternative and Complementary Therapies for Cancer

Integrative Approaches and Discovery of Conventional Drugs

Springer
This book is dedicated to patients, doctors, and scientists dealing with life-threatening cancers with courage, determination, and hope.
Cancer is a devastating disease with a severe impact on the physical and psychological well being of patients. The diagnosis of cancer brings many questions starting with diagnosis, decision on treatment, and the prospect of living with the constant possibility of recurrence. To date, only limited therapeutic options are available for most advanced cancers, and in many cases, the five-year survival rate remains difficult to achieve even with the best therapies available in the practice. Patients often seek clear and simple answers, which are not always provided by modern medicine. This often leads patients to shift attention to alternative therapies, including the holistic approach of alternative medicine, particularly preparations from herbal products, which have formed the basis for traditional medicine for thousands of years. Indeed, most ancient civilizations document the use of traditional medicine to treat a variety of illnesses and infections and have contributed to the assimilation, codification, and development of plant-based formulations. Not surprising, a significant number of naturally derived drugs are already in use in oncology practice, and herbal products continue to offer opportunities for creative discovery of novel bioactive molecules and drugs, an area that is becoming a mainstream research approach both in academic research laboratories and large biopharmaceutical firms.

Today, the use of herbal and nonherbal products for medical purpose is widespread worldwide, and continues as a distinct branch of medical practice in many parts of the world, and particularly in China where it is integrated into the public health care system. In the
Western world, the use of alternative therapies is gaining ground, especially traditional Chinese and Indian medicine, which represent some of the favored adjunctive therapies and are most compatible with conventional therapies although having distinct concepts. Typically, herbal formulations contain single or multiple active pharmacological components, as well as non-herbal ingredients. Yet most remain classified as food supplements and thus are exempt from regulations on quality control and proof of efficacy that govern standard pharmaceuticals. Although their potential benefit cannot be denied, current scientific and clinical studies using alternative therapies are inconsistent and with conflicting clinical results. Herbal preparations and formulations are available in the market, easily accessible, and widely used by cancer patients before, during, or after treatment. Even when patients inform their mainstream doctors of such use, the significance is not always obvious as the field remains a new territory for conventional medical curricula in Western medicine. In the absence of rigorous clinical studies and regulatory guidelines, the dilemma in clinical practice remains how to evaluate the efficacy of mixed formulations by determining the surrounding safety concerns, the possibility of an unjustifiable economic burden to patients, and the general risks of their interfering with or exacerbating the toxicity of standard therapies.

From a scientific perspective, the central obvious boundaries of the coexistence of nonconventional therapies with conventional practice are methodological issues relevant to the complex nature of complementary medicine, lack of rigorous and fragmented clinical trials, proof of efficacy, and legal standards that govern standard pharmaceuticals in modern oncology. These can represent the dark corners for cynical, misguided, and hegemonious use, or even harmful exploitative use of alternative therapies. With the emergence of several government-supported agencies to launch initiatives to find and support both basic and applied research on alternative therapies, and to increase regulatory guidelines and policies, such boundaries will likely evolve into beneficial integrative practice.

This book was put together by eminent and recognized experts in alternative medicine, medical oncology, cancer pharmacology, safety and regulatory issues, and modern cancer research. It is dedicated primarily to the medical community, health care
providers, and to medical students. It brings a set of timely, in-depth, and up-to-date reviews covering the progress and limitations of conventional cancer therapies, the latest developments in alternative cancer management from clinical and regulatory perspectives, and practical recommendations for health care providers.

Eminent traditional oncology experts from China and India outline the theory of traditional medicine, pattern identification, and treatment principles of various cancer types, and common formulations used in large oncology centers in China and India. Areas of controversy and potential integration into conventional oncology practice are highlighted and updated. In this respect, the benefit of alternative medicine to alleviate side effects of some chemotherapy drugs or related pain is addressed in separate chapters. In addition to the clinical aspect, the book acknowledges the importance of chemical diversity of herbal products for drug discovery in the new era of targeted therapy. Natural products will continue to be a precious source of drug development well into the future, now that great progress in genomics and proteomics open up new territory in terms of novel targets associated with the onset of the disease. In this regard, the book highlights progress in the chemistry and biology of high-throughput chemical libraries from natural products.

Montreal, QC

Moulay Alaoui-Jamali
Acknowledgement

The authors are deeply grateful to the Quebec Breast Foundation and the Canadian Cancer Breast Alliance for their continuous support and mentorship.
## Contents

### Part I  Introduction

1  Overview of Efficacy and Limitation of Standard and Targeted Therapy for Malignant Disease Using Lung Cancer as a Case Study .......................... 3
   Dao M. Nguyen

### Part II  Integrative Complementary and Alternative Medicine for Cancer Care

2  Overview of Current TCM Practice and Potential Impacts on Conventional Therapies ........................ 25
   Moulay Alaoui-Jamali and Rongyao Zhou

### Part III  Complementary and Alternative Medicine for Cancer Care in India: Basic and Clinical Perspectives

3  Complementary and Alternative Medicine for Cancer Care in India: Basic and Clinical Perspective .............. 31
   Ashok D. B. Vaidya, Ashok J. Amonkar, Narendra S. Bhatt, and Purvish M. Parikh
## Part IV Integrated TCM for Cancer Care in China: Principles, Recipes, and Case Studies for Selected Sites

<table>
<thead>
<tr>
<th>Number</th>
<th>Cancer Type</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Esophageal Cancer</td>
<td>Jia He Shu</td>
<td>85</td>
</tr>
<tr>
<td>5</td>
<td>Gastric Cancer</td>
<td>Yi Zhong</td>
<td>105</td>
</tr>
<tr>
<td>6</td>
<td>Colorectal Cancer</td>
<td>Yi Zhong</td>
<td>135</td>
</tr>
<tr>
<td>7</td>
<td>Liver Cancer</td>
<td>Minghua Jin and He Qiang</td>
<td>153</td>
</tr>
<tr>
<td>8</td>
<td>Pancreatic Cancer</td>
<td>Peiwen Li</td>
<td>185</td>
</tr>
<tr>
<td>9</td>
<td>Breast Cancer</td>
<td>Xiao Zou, Renmin Wei, Ketao Lan, Xuezhen Ma, and Chunling Zhang</td>
<td>205</td>
</tr>
<tr>
<td>10</td>
<td>Ovarian Cancer</td>
<td>Yi Zhong</td>
<td>223</td>
</tr>
<tr>
<td>11</td>
<td>Prostate Cancer</td>
<td>Jia He Shu</td>
<td>249</td>
</tr>
<tr>
<td>12</td>
<td>Kidney Cancer</td>
<td>Hao Yingxu</td>
<td>271</td>
</tr>
<tr>
<td>13</td>
<td>Bladder Cancer</td>
<td>Jia He Shu</td>
<td>319</td>
</tr>
<tr>
<td>14</td>
<td>Brain Cancer</td>
<td>Yi Zhong</td>
<td>351</td>
</tr>
</tbody>
</table>
Contents

Part V   Management of Complementary and Alternative Treatments for Cancer

15   Complementary and Alternative Treatments for the Management of Cancer-Related Fatigue ............ 371
Amit Sood and Debra Barton

16   Complementary and Alternative Treatments for the Management of Cancer-Related Pain ............ 393
Mark A. Ware

Part VI   Clinical, Pharmacological, and Safety Issues Using Complementary Therapies

17   Challenges Conducting Clinical Trials with Herbal Products in Oncology .............................. 403
Amit Sood and Kavita Prasad

18   Herbal Product–Drug Interactions from a Pharmacological Perspective ................................. 423
Caroline N. Lougheed and Moulay Alaoui-Jamali

Part VII   Patient–Physician Relationship

19   Patient–Physician Relationship: Creating an Optimal Healing Environment ............................ 497
Hal Gunn

Part VIII   Regulatory Issues

20   Legal Issues in Alternative Treatment of Cancer .......... 513
Allan M. Freedman

21   Intellectual Property for Alternative Medicine .......... 529
Gina Shishima and Tamsen Barrett
Part IX  From Practice to Basics

22 Chemical-Biology of Natural Products from Medicinal Plants for Cancer Therapy ........................ 557
   Thomas Efferth and Michael Wink

23 Flavonoids in Cancer Prevention and Therapy: Chemistry, Pharmacology, Mechanisms of Action, and Perspectives for Cancer Drug Discovery ........................ 583
   Guy G. Chabot, Yasmine S. Touil, Minh Hien Pham, and Daniel Dauzonne

24 Marine Natural Products and their Synthetic Derivatives for Cancer Therapy ............................... 613
   Tao Jiang, Puyong Zhang, Shaopeng Chen, and Guoqiang Li

25 Natural Product-like Scaffolds for Molecular Dissection of Macromolecular Interactions and New Therapeutic Applications ............................... 645
   Krikor Bijian and Prabhat Arya

26 Mining Natural Product-Derived Molecules Against Cancer Targets: The Case of the Androgen Receptor in Prostate Cancer ............................... 671
   Jian Hui Wu

Subject Index ............................................................. 693
Contributors

Guy G. Chabot, Chemical and Genetic Pharmacology Laboratory, Faculty of Pharmacy, Paris Descartes University, Paris, France, guy.chabot@parisdescartes.fr

Shaopeng Chen, School of Medicine and Pharmacy, Ocean University of China, Qingdao, PR China, jiangtao@mail.ouc.edu.cn

Daniel Dauzonne, Institut Curie, Centre de Recherche, Paris, France, daniel.dauzonne@curie.fr

Thomas Efferth, Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany, t.efferth@dkfz-heidelberg.de

Allan M. Freedman, Concord, ON, Canada, amfdrm@aol.com

Hal Gunn, InspireHealth, Vancouver, BC, Canada, hgunn@inspirehealth.ca

Tao Jiang, Kay Laboratory of Marine Drug, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, PR China, jiangtao@mail.ouc.edu.cn

Minghua Jin, TCM Department, The Institute of Western Integrated Traditional Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, jshouzhi@163.com

Ketao Lan, Department of Oncology, Qingdao Central Hospital of Central Medical Group, Qingdao, China, wm0166@sina.com

Peiwen Li, Department of TCM Oncology, China–Japan Friendship Hospital, Beijing University, Beijing, PR China, aiyu0108@gmail.com

Guoqiang Li, Kay Laboratory of Marine Drug, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, PR China, jiangtao@mail.ouc.edu.cn

Caroline N. Lougheed, Departments of Experimental Medicine, Oncology, and Pharmacology, Therapeutics Faculty of Medicine, Segal Cancer Center, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, QC, Canada, caroline.lougheed@mail.mcgill.ca
Xuezhen Ma Department of Oncology, Qingdao Central Hospital of Central Medical Group, Qingdao, China, wm0166@sina.com

Dao M. Nguyen Thoracic Surgery Section, Division of Cardiothoracic Surgery, The DeWitt Daughtry Family Department of Surgery, Leonard M. Miller Faculty of Medicine, University of Miami, Miami, FL, USA, dnguyen4@med.miami.edu

Purvish M. Parikh MRC – Kasturba Health Society, Mumbai, India

Minh Hien Pham Laboratoire de Pharmacologie Antitumorale, Institut pour la Recherche sur le Cancer de Lille, Lille, France, mh_pham@yahoo.fr

Kavita Prasad Integrative Medicine, Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA, prasad.kavita@mayo.edu

He Qiang Hepatobiliary Department, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China, lheqiang@hotmail.com

Gina Shishima Fulbright & Jaworski, LLP, Austin, TX, USA, gshishima@fulbright.com

Jia He Shu Oncology Department, Shanghai Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Affiliated Hospital, Shanghai, China, zhoury1357@hotmail.com

Amit Sood Integrative Medicine, Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA, sood.amit@mayo.edu

Yasmine S. Touil Faculté de Médecine, Lille, France, yasmine.touil@live.fr

Ashok D.B. Vaidya ICMR Advanced Centre of Reverse Pharmacology in Traditional Medicine, MRC – Kasturba Health Society, Mumbai, India; Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA; Gujarat Cancer Research Institute, Ahmedabad, India, mmrckhs@gmail.com
Mark A. Ware Departments of Anesthesia and Family Medicine, Health Centre Pain Clinic, McGill University, Montreal, QC, Canada, mark.ware@muhc.mcgill.ca

Renmin Wei Department of Oncology, Qingdao Central Hospital of Central Medical Group, Qingdao, China, wm0166@sina.com

Michael Wink Department of Biology, Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg, Germany, wink@uni-hd.de

Jian Hui Wu Department of Oncology, Segal Comprehensive Cancer Center, Lady Davis Institute for Medical Research, The Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, QC, Canada, jian.h.wu@mcgill.ca

Hao Yingxu Department of Oncology, China–Japan Friendship Hospital, Beijing, PR China, aiyu0108@gmail.com

Chunling Zhang Department of Oncology, Qingdao Central Hospital of Central Medical Group, Qingdao, China, wm0166@sina.com

Puyong Zhang School of Medicine and Pharmacy, Ocean University of China, Qingdao, PR China, jiangtao@mail.ouc.edu.cn

Yi Zhong Oncology Department, Shanghai Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Affiliated Hospital, Shanghai, China, zhongzixian2000@yahoo.com.cn

Rongyao Zhou Oncology Department, Shanghai Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Affiliated Hospital, Shanghai, China, zhoury1357@hotmail.com

Xiao Zou Qingdao Tumor Hospital, Qingdao Central Hospital of Central Medical Group, Qingdao, China, wm0166@sina.com